Ensign Peak Advisors
CGEM icon

Ensign Peak Advisors’s Cullinan Oncology CGEM Stock Holding History

Ensign Peak Advisors’s Portfolio CGEM Stock Details CGEM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-148,773
Closed -$2.49M – 1712
2024
Q3 		$2.49M Hold
148,773
– – ﹤0.01% 854
2024
Q2 		$2.59M Buy
+148,773
New +$3.17M ﹤0.01% 810
2022
Q4 		– Sell
-2,400
Closed -$31K – 1868
2022
Q3 		$31K Buy
2,400
+330
+16% +$4.45K ﹤0.01% 2274
2022
Q2 		$27K Hold
2,070
– – ﹤0.01% 2112
2022
Q1 		$22K Hold
2,070
– – ﹤0.01% 2174
2021
Q4 		$32K Sell
2,070
-10,142
-83% -$202K ﹤0.01% 2164
2021
Q3 		$276K Buy
12,212
+7,212
+144% +$193K ﹤0.01% 1716
2021
Q2 		$129K Hold
5,000
– – ﹤0.01% 1764
2021
Q1 		$208K Buy
+5,000
New +$203K ﹤0.01% 1724

Other funds holding CGEM

MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Ensign Peak Advisors's CGEM Position: Q4 2024 in Review

Ensign Peak Advisors sold out of Cullinan Oncology (CGEM) in Q4 2024, closing a stake of 148,773 shares — an estimated $2.49M sold.

Ensign Peak Advisors first reported a position in CGEM in Q1 2021 and held it in 9 quarters. The position peaked at $2.59M in Q2 2024. 146 funds tracked by Wall St. Rank hold CGEM as of Q4 2024.

  • Ensign Peak Advisors reported no remaining Cullinan Oncology position as of Q4 2024 after selling out during the quarter.
  • Ensign Peak Advisors sold 148,773 Cullinan Oncology shares in Q4 2024, an estimated $2.49M.
  • Ensign Peak Advisors first reported a position in Cullinan Oncology in Q1 2021 and held it in 9 quarters.
  • Ensign Peak Advisors's Cullinan Oncology position peaked at $2.59M in Q2 2024.
  • 146 funds tracked by Wall St. Rank held Cullinan Oncology as of Q4 2024.

Based on Ensign Peak Advisors's 13F filing for Q4 2024, filed 14 Feb 2025.